Why the study?
Following trial findings of non-inferiority of TAVI to SAVR at 24 months, the cost-effectiveness of self-expandable TAVI in low-risk patients had not been evaluated within the French healthcare system.
Is TAVI cost-effective compared to SAVR in patients at low surgical risk in the French healthcare system?
Population
N = 725 TAVI and N = 678 SAVR low-risk patients from the Evolut Low Risk trial
Comparison
Self-expandable TAVI vs SAVR
Design
Decision-analytic model-based cost-effectiveness analysis
Authors
Loading...
May support French reimbursement of low-risk TAVI; leaves open lifetime survival assumptions and applicability beyond France.
Is TAVI cost-effective compared to SAVR in patients at low surgical risk in the French healthcare system?
TAVI is a cost-effective alternative to SAVR for patients at low surgical risk within the French healthcare system.
Tchétché et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: